文献速递胸部CT

增强CT影像组学预测肺腺癌高级别成分及预后分层

Contrast-enhanced CT Radiomics for High-Grade Pattern Identification and Prognostic Stratification in Lung Adenocarcinoma with Consolidation-to-Tumor Ratio of 25% or More.
PubMed 文献 · Radiology · 2026-01-01

本研究基于三家中心1181例临床Ⅰ期浸润性肺腺癌患者的术前增强CT,构建并验证了影像组学联合临床与CT语义特征的组合模型,用于预测高级别成分(HGPs以20%为界二分,或HGP0/HGP1/HGP2三分)。组合模型在外部测试集二分AUC达0.84、三分微平均AUC达0.72,其预测高风险组是总生存与无复发生存的独立预后因素。

要点

  • 组合模型预测的HGP高风险组与OS和RFS显著相关,可用于术前风险分层。
  • 实性成分比例≥25%的临床Ⅰ期浸润性肺腺癌适用本研究模型。
  • 模型输出可作为病理高级别成分的术前替代指标,辅助手术决策。

核心结论

  • 整合临床变量、CT语义特征与影像组学预测概率的组合模型可有效预测肺腺癌高级别成分。
  • 模型预测高风险组是OS和RFS的独立预后因素,在亚组分析中结论一致。

研究设计与样本

  • 研究类型为回顾性多中心研究,纳入2017年1月至2025年5月接受手术的临床Ⅰ期浸润性肺腺癌患者共1181例。
  • 训练集667例,内部测试集279例,外部测试集235例;中位年龄61岁,女性694例。
  • 基于术前增强CT图像提取影像组学特征,参考标准为术后病理HGPs比例。
  • 影像组学模型采用XGBoost分类器构建,组合模型整合影像组学预测概率、临床变量与CT语义特征。

关键影像表现/征象

  • CT语义特征作为组合模型组成部分参与预测,原文未展开描述具体征象。

诊断标准与关键数值

  • 高级别成分二分标准:低风险为HGPs<20%,高风险为HGPs≥20%。
  • 高级别成分三分标准:HGP0为HGPs=0,HGP1为0<HGPs<20%,HGP2为HGPs≥20%。
  • 组合模型二分任务诊断效能:训练集AUC为0.87,内部测试集AUC为0.80,外部测试集AUC为0.84。
  • 组合模型三分任务诊断效能:训练集微平均AUC为0.80,内部测试集微平均AUC为0.74,外部测试集微平均AUC为0.72。
  • 模型预测高风险组对OS的HR二分法为1.98、三分法为2.93;对RFS的HR二分法为3.33、三分法为5.10。

临床应用与阅片要点

  • 对实性成分比例≥25%的临床Ⅰ期浸润性肺腺癌,可用组合模型术前评估HGPs风险。
  • 模型输出的高风险标签可作为预后分层的影像学依据,辅助临床制定手术与随访策略。

局限性

  • 研究为回顾性设计,原文未报告其他明确局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Radiomics may preoperatively identify high-grade patterns (HGPs) in lung adenocarcinoma (ADC) and assist in clinical decision-making. Purpose To develop and evaluate a machine learning model based on preoperative contrast-enhanced CT images to predict HGPs and explore the model's prognostic value. Materials and Methods Patients with clinical stage I invasive ADC who underwent surgery (January 2017 to May 2025) were retrospectively enrolled from three centers. Binary (low risk: HGPs < 20%; high risk: HGPs ≥ 20%) and ternary (HGP0: HGPs = 0; HGP1: 0 < HGPs < 20%; HGP2: HGPs ≥ 20%) classification analyses were performed based on the proportion of HGPs. Multivariable logistic regression analysis was used to determine independent predictors of HGPs. XGBoost classifier-based radiomic models and combined models (radiomics-predicted probabilities plus clinical variables plus CT semantic features) were constructed and evaluated for discriminability, calibration ability, and clinical utility. Kaplan-Meier and Cox regression analyses were conducted to identify prognostic factors for overall survival (OS) and recurrence-free survival (RFS). Results A total of 1181 patients (median age, 61 years [IQR, 54-66 years]; 694 female) were allocated to the training (n = 667), internal test (n = 279), and external test (n = 235) sets. The combined model achieved the best discrimination in both binary (training: area under the receiver operating characteristic curve [AUC], 0.87 [95% CI: 0.84, 0.90]; internal test: AUC, 0.80 [95% CI: 0.74, 0.85]; external test: AUC, 0.84 [95% CI: 0.78, 0.90]) and ternary (training: microaverage AUC, 0.80 [95% CI: 0.78, 0.82]; internal test: microaverage AUC, 0.74 [95% CI: 0.70, 0.77]; external test: microaverage AUC, 0.72 [95% CI: 0.68, 0.76]) classification analyses. Model-predicted high-risk group was an independent prognostic factor for both OS (binary: hazard ratio [HR] = 1.98, P =.04; ternary: HR = 2.93, P =.03) and RFS (binary: HR = 3.33, P < .001; ternary: HR = 5.10, P < .001) and was consistently confirmed across subgroup analyses. Conclusion The combined model, integrating clinical variables, CT semantic features, and radiomics-predicted probabilities, effectively predicted high-grade patterns in lung ADC and showed strong potential for prognostic risk stratification. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Arita and Kocak in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. E, Kang, Liu, et al. Contrast-enhanced CT Radiomics for High-Grade Pattern Identification and Prognostic Stratification in Lung Adenocarcinoma with Consolidation-to-Tumor Ratio of 25% or More. Radiology. 2026. PMID: 42578790. doi:10.1148/radiol.260264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。